Supplemental material for JAAD publication titled:  Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

Name: Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study
Creator: Nina Magnolo
Published: 2021-09-03T08:00:06.347Z
Keywords: Dermatology, Pediatrics, Psoriasis

Magnolo, Nina

doi:10.17632/vn3spwfg52.4

Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

Published: 3 September 2021| Version 4 | DOI: 10.17632/vn3spwfg52.4

Contributor:

Nina Magnolo

Description

Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results" to be published in Journal of the American Academy of Dermatology

Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

Description

Files

Categories

Licence